USFDA approves DRL's Azacitidine for injection

HYDERABAD: Dr Reddy's Laboratories today announced that the US Food and Drug Administration has approved Azacitidine for injection 100 mg/vial, a bio-equivalent generic version of Vidaza (azacitidine for injection).


Azacitidine is used to treat certain types of bone marrow cancers and blood cell disorders.

Celgene Corporation's Vidaza brand had US sales of approximately $378.5 million for the most recent twelve months ending July 2013, according to IMS Health.

"The launch of product in the market is planned in the near-term," Dr Reddy's said in a statement without specifying time-frame to launch the drug.

Dr Reddy's Azacitidine for injection 100 mg/vial is available in single use-vials, it said.

Shares of the company were quoting at Rs 2,311.25 at 1245 hrs, up 3.96 per cent on BSE.